This issue of the Surgical Pathology Clinics entitled "Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Tumors" is being edited by Dr. Lynette Sholl and will cover molecular pathology in a wide array of anatomic locations including, salivary gland, lung, bladder, glioma, endometrium, colon, pancreaticobiliary tract, sarcoma, myeloid neoplasams, and lymphomas.

Retinoids have received considerable attention in recent years and due cognizance has been given to their versatility as biological response modifiers, as evidenced by the virtually explosive growth of literature in this field in the past few years. This volume has been designed to give a current state-of-the-art picture of retinoids. The perceived potential of retinoids in the treatment of certain disease stated has initiated attempts at identifying and synthesizing new retinoid derivatives with definable and selective effects on aberrant biological phenomena. Appropriately, therefore, we begin with the chemistry of retinoids and their derivatives together with discussions of their biological activity. Major advances have been made in understanding the mechanisms by which retinoids modulate physiological and phenotypic traits of cells. The transduction of retinoid signaling by the mediation of nuclear receptors of the steroid/thyroid receptor superfamily has now been studied extensively and the cloning and defining the characteristics of these receptors has been a focus of discussion in this volume. Retinoids also markedly modulate the transduction of extracellular signals such as those imparted by growth factors and hormones, and thus actively influence and control cellular proliferative patterns. Retinoids can alter epidermal growth factor receptor expression (Kawaguchi et al., 1994), responsiveness to thyroid hormone (Esfandiari et al., 1994; Pallet et al., 1994), inhibit the proliferative responses of hematopoietic progenitor cells to granulocyte colony stimulating factor (Smeland et al., 1994), and modulate secretion on interleukins by leukaemic cells (Balitrand et al., 1994), among other things. This has obvious implications for pharmacological manipulation of deregulated growth (Dickens and Colletta, 1993; Mulshine et al., 1993). Apoptosis is another component in the regulation of growth control. Apoptotic cell death is influenced by several agents and retinoids may function by interfering with apoptotic pathways of regulation of growth control and quite legitimately, therefore, the importance of this aspect of retinoid function has been duly recognized here.

Gynecologic malignancies, especially endometrial and ovarian cancers are among the most important and most severely affected by obesity. This volume of Energy Balance and Cancer, written by the world's leading experts in this field, is arranged to provide a transdisciplinary assessment of the pertinent issues, results of relevant research on mechanisms, and control, strategies for dealing with affected patients and improving outcomes and future research needs. The volume comprehensively covers the epidemiology linking obesity to endometrial and ovarian cancer as well as the public awareness of this critical problem. Subsequent chapters explain biologic aspects of linkages between energy balance and gynecologic malignancies. The volume further outlines strategies to disrupt the linkage between obesity and gynecologic malignancies and concludes with a series of chapters focused on management strategies for obese patients with gynecologic malignancies. This volume provides a valuable resource for all physicians, scientists and other transdisciplinary investigators and practitioners interested and involved in energy balance and cancer. It should be a particularly useful guide to optimize outcomes for all practitioners dealing with patients with gynecologic malignancies challenged by energy balance issues. Moreover, it should serve as a useful guide to students and investigators interested in conducting further research on defining and disrupting the important linkage between energy balance and gynecologic malignancies.

This issue of Radiologic Clinics of North America focuses on Extranodal Lymphoma from Head to Toe, and is edited by Dr. Mark Murphey. Articles will include: Pathology of Extranodal Lymphoma; Pulmonary and Mediastinal Extranodal Lymphoma; Gastrointestinal Extranodal Lymphoma; Extranodal Lymphoma Involving the CNS and Spine; Genitourinary Extranodal Lymphoma; Musculoskeletal Extranodal Lymphoma; Pediatric Extranodal Lymphoma; Extranodal Lymphoma of the Breast; Cardiac Extranodal Lymphoma, and more!

This volume presents state-of-the-art information on each of the arms of the unfolded protein response (UPR), how their activation/repression are regulated, integrated, and coordinated, how UPR components affect cancer cell biology and responsiveness to therapeutic interventions, and how UPR components/activities offer potentially novel targets for drug discovery, repurposing, and development. The volume will provide the most recent information on the signaling and regulation of the UPR, explore examples of how the UPR and/or specific components contribute to cancer biology, and identify and explore specific examples of potently new actionable targets for drug discovery and development from within the UPR and its regulation. Unique to the volume will be a specific focus on the UPR and its role in cancer biology, as well as a discussion of the role of the UPR in drug responses and resistance in cancer.

Michael Sand gives the reader an overview of current techniques in expression profiling of miRNAs and their maturation machinery in the skin. This book is a postdoctoral thesis on miRNAs in cutaneous malignant melanoma and non-melanoma skin cancer with a focus on the miRNA processing machinery and miRNA expression profiling. The research presented in this book was performed in the Dermatologic Surgery Section at the Department of Dermatology, Venereology and Allergology of the Ruhr-University Bochum, Germany and gives the reader an overview of current techniques in expression profiling of miRNAs and their maturation machinery in the skin.

This book approaches the differential diagnosis and management of rare, hereditary cancer syndromes from a practical angle, addressing the issues pertinent to each tumour type as encountered by health professionals in their day-to-day practice. This book enables readers to correctly identify patients with rare cancer syndromes who would benefit from genetic counselling and testing, and provides the necessary knowledge for appropriate patient management and advising at-risk family members. It begins by describing recent advances in genetic testing for cancer-predisposing genes. Leading experts from Europe and Australia then offer detailed, up-to-date guidance on the diagnosis and management of a wide range of hereditary cancers. The concluding chapter examines the wider issues that are raised by genetic testing for rare cancer syndromes for patients, families and health professionals. This book is an invaluable source of information for all specialists involved in the care of such patients and their families.

In 1950, a diagnosis of cancer was all but a death sentence. Mortality rates only got worse, and as late as 1986, an article in the New England Journal of Medicine lamented: We are losing the war against cancer." Cancer is one of humankind's oldest and most persistent enemies it has been called the existential disease.But we are now entering a new, and more positive, phase in this long campaign. While cancer has not been cured,and a cure may elude us for a long time yet,there has been a revolution in our understanding of its nature. Years of brilliant science have revealed how this individualistic disease seizes control of the foundations of life,our genes,and produces guerrilla cells that can attack and elude treatments. Armed with those insights, scientists have been developing more effective weapons and producing better outcomes for patients. Paul A. Marks, MD, has been a leader in these efforts to finally control this devastating disease.Marks helped establish the strategy for the war on cancer" in 1971 as a researcher and member of President Nixon's cancer panel. As the president and chief executive officer for nineteen years at the world's pre-eminent cancer hospital, the Memorial Sloan-Kettering Cancer centre, he was instrumental in ending the years of futility. He also developed better therapies that promise a new era of cancer containment. Some cancers, like childhood leukemia and non-Hodgkin's lymphoma, that were once deadly conditions, are now survivable,even curable. New steps in prevention and early diagnosis are giving patients even more hope. On the Cancer Frontier is Marks' account of the transformation in our understanding of cancer and why there is growing optimism in our ability to stop it.

Childhood acute leukemias are one of the main causes of death in children aged 1 to 14 years in some countries; and unfortunately, we have been unable to prevent it. Certainly, a good parcel of it is due to the poor understanding about its etiology. This book aims to describe the most important theories and hypothesis regarding childhood acute leukemia. Written by the most outstanding researchers in the field, this book intends to contribute to a greater understanding of the etiology of this disease. It goes beyond the simple and common analysis of risk factors, which hardly allows us to draw definite conclusions. By addressing the etiology of the disease, discussing from molecular biology until epidemiology and clinical manifestations, this book will guide present and future approaches, contributing for a better clinical management of leukemia in children. The knowledge regarding etiology is a crucial step for a better evaluation, prevention and treatment of a disease. Thus, this book finally intends to provide such knowledge, allowing physicians and practitioners to a better manage of childhood acute leukemias.

The complexity of cancer demands an integrated approach from both a cancer biology standpoint and a pharmaceutical basis to understand the different anticancer modalities. Current research has been focused on conventional and newer anticancer modalities, recent discoveries in cancer research, and also the advancements in cancer treatment. There is a current need for more research on the advances in cancer therapeutics that bridge the gap between basic research (pharmaceutical drug development processes, regulatory issues, and translational experimentation) and clinical application. Recent promising discoveries such as immunotherapies, promising therapies undergoing clinical trials, synthetic lethality, carbon beam radiation, and other exciting targeted therapies are being studied to improve and advance the studies of modern cancer treatment. The Handbook of Research on Advancements in Cancer Therapeutics serves as a comprehensive guide in modern cancer treatment by combining and merging the knowledge from both cancer biology and the pharmacology of anticancer modalities. The chapters come from multi-disciplinary backgrounds, including scientists and clinicians from both academia and various industries, to discuss nascent personalized therapies and big data-driven cancer treatment. While highlighting topic areas that include cancer prevention, cancer therapeutics, and cancer treatments through the lenses of technology, medicine/drugs, and alternate therapies, this book is ideally intended for oncologists, radiation oncologists, surgical oncologists, and cancer biologists, along with practitioners, stakeholders, researchers, academicians, and students who are interested in understanding the most fundamental aspects of cancer and the available therapeutic opportunities.

The study of the molecular events leading to cellular transformation and cancer has progressed significantly in the last decade, and it has become apparent that many genes subject to modification in cancer are, in fact, transcription factors that govern the execution of the genetic programme of the cell. Transcription factors can behave either as oncogenes or as tumour suppressor genes. To date only a limited number of transcription factors have been associated with cancer. This volume deals with several transcription factor families that were first identified in oncogenic retroviruses. Each chapter contains a description of the structure of the transcription factors, the nature of target genes, the regulation of their activities, and an explaination of how they can deregulate cell growth and differentiation. This text should be suitable for the specialist scientist and the advanced student

This book describes in detail current best practice in the diagnosis and treatment of malignant pediatric bone tumors and also discusses other important aspects of management. Clinical assessment, the role of different imaging modalities and choice of biopsy procedure are explained and an individual chapter is devoted to diagnostic pathology. The treatment-oriented chapters offer in-depth descriptions of chemotherapeutic regimens, radiation therapy, limb-salvage options and amputation-related issues and in addition consider the approach to lung nodules, the role of biomarkers, off-therapy monitoring and the treatment of relapse. Psychosocial impacts and needs are addressed and guidance provided on nursing during treatment and rehabilitation following orthopaedic surgery. Closing chapters evaluate emerging therapies and discuss disparate aspects of survivorship. The authors are acknowledged experts and include many contributors from the Nationwide Children's Hospital, a leading pediatric care facility in the United States.

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Mark Krasna, is devoted to Lung Cancer. Dr. Krasna has assembled expert authors to review the following topics: Epidemiology for Lung Cancer; Screening for Lung Cancer; Pathology for Lung Cancer; Treatment of Patients with Oligometastatic Disease for NSCLC; SBRT/Ablative Therapies for NSCLC; Mediastinal Staging for Lung Cancer; VATS Lobectomy for NSCLC; Robotic Lung Resection for NSCLC; Pneumonectomy for NSCLC; Bronchoscopy-Diagnostic and Therapeutic for NSCLC; Neoadjuvant Therapy for Lung Cancer; Molecular/Targeted Therapy for Lung Cancer; Adjuvant Therapy for Stage 1and 2 NSCLC, and more!

There are more than 63,000 new cases of uterine and endometrial cancer each year in the United States, up from approximately 41,000 when the first edition of Uterine Cancer was published in 2009. A book focusing on these cancers was timely, with emergent sophistication in diagnosis increasingly impacting clinical decision-making. However, five years later, the need for an updated book on this topic is even stronger as oncologists recognize opportunities to impact the outcome on women that are increasingly diagnosed with these malignancies. Uterine Cancer: Screening, Diagnosis, and Treatment, Second Edition, part of the Current Clinical Oncology series, enhances the awareness on this somewhat neglected area of therapeutics, helping to integrate targeted therapies into the management of women with uterine cancer. Written by experts in the field in a highly practical and comprehensive manner, it is a must-have for all gynecological residents and fellows, as well as gynecological oncologists, medical oncologists, radiation oncologists, and family practice doctors who wish to provide their patients with the best possible care.

Hsp90 in Cancer: Beyond the Usual Suspects, the latest volume in the Advances in Cancer Research series, focuses on the multifunctional molecular chaperone Hsp90 which regulates the post-translational stability and function of a broad repertoire of client proteins and discusses some of the lesser-known aspects of how Hsp90 and its related family members enable oncogenic transformation and malignant progression.

This book presents a comprehensive discussion on the heterogeneity existing between different types of stem cells within the same tissue, for several types of cancers, e.g. glioblastoma stem cells. Recent developments have revealed completely different roles of distinct stem cells within the same organ. Thus, Stem Cells Heterogeneity in Cancer provides a timely update us on the current information on stem cells heterogeneity in various tissues. It also provides a solid foundation of the history of stem cells from specific tissues and the current applications of this knowledge in regenerative medicine. When taken as a whole, alongside its companion volumes Stem Cells Heterogeneity - Novel Concepts, and Stem Cells Heterogeneity in Different Organs, these three books present a comprehensive reference on stem cell heterogeneity in various tissues and current and future applications for regenerative medicine. It is essential reading for advanced cell biology students as well as researchers in stem cells and clinicians.

This issue of Surgical Pathology Clinics is devoted to Soft Tissue Tumors, the first in this series was presented in 2011. This issue addresses the most difficult diagnostic challenges and focuses on differential diagnosis in soft tissue tumors. Each presentation is accompanied by abundant histologic slides to display the diagnostic differences. Additionally, authors selected two to five diagnoses they find can be particularly difficult, with an emphasis on how to approach such lesions on biopsy samples where relevant and the role of ancillary studies. Topics include coverage of diagnostically challenging: Vascular lesions; Retroperitoneal "Fatty" tumors of adults; Smooth muscle neoplasms; Chondro-osseous lesions of soft tissue; Pediatric tumors; Epithelioid tumors; Spindle cell neoplasms of the retroperitoneum; and Peripheral nerve sheath tumors. Also presented are: Non-mesenchymal mimics of benign and malignant soft tissue tumors; Soft tissue tumors with overlapping molecular findings; Recently characterized soft tissue tumors; Benign mimics of sarcoma; Advances in molecular methods in the analysis of soft tissue tumors and therapeutic implications; and Myoepithelial tumors: an update. Leona Doyle and Karen Fritchie lead this issue of experts in soft tissue pathology.

This issue of Surgical Clinics of North America, guest edited by Dr. Clifford Cho, is devoted to Technical Aspects of Oncological Hepatic Surgery. He has assembled expert authors to review the following topics: Determination of Resectability; Radiographic Characterization of Hepatic Tumors; Chemotherapy-associated Hepatotoxicity; Preoperative Assessment and Optimization of the Future Liver Remnant; Anatomy of Hepatic Resectional Surgery; Resection of Gallbladder Carcinoma; Resection of Hilar Cholangiocarcinoma; Technical Aspects of Orthotopic Liver Transplantation for Hepatocellular Carcinoma; Hemostasis and Hepatic Surgery; Minimally Invasive Hepatic Surgery; Hepatic Tumor Ablation; Hepatic Transarterial Therapies; Hepatic Perfusion Therapy; Hepatic Artery Infusional Chemotherapy; Ex vivo Hepatic Surgery, and more!

Cancer is a multifaceted and genomically complex disease and data obtained through high throughput technologies has provided near complete resolution of the landscape of how genomic, genetic and epigenetic mutations in cancerous cells effectively influence homeostasis of signaling networks within these cells, between cancerous cells, tumor microenvironment and at the organ level. Increasingly sophisticated information has helped us in developing a better understanding of the underlying mechanisms of cancer, and it is now known that intra-tumor genetic heterogeneity, cellular plasticity, dysregulation of spatio-temporally controlled signaling cascades, and loss of apoptosis are contributory in cancer development, progression and the development of resistance against different therapeutics. It is becoming progressively more understandable that earlier detection of pre-existing or emerging resistance against different therapeutics may prove to be helpful in personalizing the use of targeted cancer therapy. Despite the fact that there is a continuously increasing list of books, being guest edited by researchers, books on the subject are often composed of invited reviews without proper sequence and continuity and designed for a particular readership. This book progressively shifts and guides the readers from basic underlying mechanisms to translational approaches to treat cancer.

This book is a comprehensive understanding of the evolution of pre-malignant disease, emphasizing common themes in the field, including stem cell biology and histologic modes of cancer progression between the distal esophagus and stomach. Its sixteen chapters discuss metaplastic tissue change in the upper GI, clonalexpansion of early neoplasia, stem cell dynamics in experimental models, pathology of early esophageal squamous cell carcinoma, therapeutic modalities for esophageal squamous cell carcinoma, pathology of Barrett's esophagus, screening, early detection and novel diagnostic tools for Barrett's esophagus, clonal evolution of Barrett's esophagus, endoscopic therapeutic modalities of early esophageal cancer, pathology of early gastric cancer, and experimental models for gastric cancer. Stem Cells, Pre-neoplasia and Early Cancer of the Upper Gastrointestinal Tract is an integrative text on both the current state of translational research on every cancer development of the upper gastrointestinal tract as well as on novel clinical diagnostic and therapeutic modalities. It highlights a rapidly growing field within cancer research and is essential reading for oncologists, biochemists and advanced graduate students alike. Springer's Advances in Experimental Medicine and Biology series presents multidisciplinary and dynamic findings in the broad fields of experimental medicine and biology. The wide variety in topics it presents offers readers multiple perspectives on a variety of disciplines including neuroscience, microbiology, immunology, biochemistry, biomedical engineering and cancer research.

This volume provides detailed descriptions of prevailing and novel techniques used by experts in the study of PTEN function in disease and biology. The book begins with chapters exploring methods to detect expression levels of PTEN in normal and diseased human specimens; methods to evaluate specific PTEN function in brain cancer; methods that utilize a new biosensor to measure PTEN regulation; and techniques to measure post-transcriptional regulation of PTEN by micoRNAs and ceRNAs. Other chapters present methods describing novel techniques to detect PTEN localization and previously unstudied structural features of PTEN measured through X-Ray Crystallography and Hydrogen Deuterium Exchange Mass Spectrometry. The book concludes with methods to study PTEN function in model organisms including mice and C. elegans. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and thorough, PTEN: Methods and Protocols is a valuable collection of methodologies and protocols useful to researchers who are interested in the PTEN field.